<![CDATA[Managing Subcutaneous Amivantamab Toxicities in Head and Neck Cancer]]>

Summary

Dr. Barbara Burtness discussed management strategies for skin reactions and MET-driven edema associated with subcutaneous amivantamab in head and neck cancer patients. This is a clinical education piece on handling known toxicities of an existing therapeutic.